Charles Schwab Investment Management Inc Gt Biopharma, Inc. Transaction History

Charles Schwab Investment Management Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.64 - $3.11 $20,270 - $38,439	-12,360 Reduced 32.33%	25,869 $78,000
Q1 2022 May 13, 2022	SELL	$2.6 - $3.3 $19,331 - $24,535	-7,435 Reduced 16.28%	38,229 $111,000
Q3 2021 Nov 16, 2021	SELL	$6.68 - $15.26 $82,357 - $188,140	-12,329 Reduced 21.26%	45,664 $308,000
Q2 2021 Aug 16, 2021	BUY	$7.19 - $18.96 $416,969 - $1.1 Million	57,993 New	57,993 $899,000

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $96.4M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.